Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (3y) (2012 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 36.60% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -35.85% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -96.44% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 52.78% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -28.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 67.39% |
| Mar 31, 2026 | 32.17% |
| Dec 31, 2025 | 41.34% |
| Sep 30, 2025 | -8.65% |
| Jun 30, 2025 | 9.53% |
| Mar 31, 2025 | 28.85% |
| Dec 31, 2024 | 24.54% |
| Sep 30, 2024 | -30.85% |
| Jun 30, 2024 | -7.42% |
| Mar 31, 2024 | -2.05% |
| Dec 31, 2023 | -321.76% |
| Sep 30, 2023 | 85.91% |
| Jun 30, 2023 | -28.61% |
| Mar 31, 2023 | -35.68% |
| Dec 31, 2022 | 17.89% |
| Sep 30, 2022 | 62.90% |
| Jun 30, 2022 | -50.38% |
| Mar 31, 2022 | -43.09% |
| Dec 31, 2021 | -66.44% |
| Sep 30, 2021 | 114.53% |